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Abstract
Background: Most subsequent new primary or recurrent melanomas might be self-detected if patients are trained
to systematically self-examine their skin and have access to timely medical review (patient-led surveillance).
Routinely scheduled clinic visits (clinician-led surveillance) is resource-intensive and has not been shown to improve
health outcomes; fewer visits may be possible if patient-led surveillance is shown to be safe and effective. The MEL-
SELF trial is a randomised controlled trial comparing patient-led surveillance with clinician-led surveillance in people
who have been previously treated for localised melanoma.
Methods: Stage 0/I/II melanoma patients (n = 600) from dermatology, surgical, or general practice clinics in NSW
Australia, will be randomised (1:1) to the intervention (patient-led surveillance, n = 300) or control (usual care, n =
300). Patients in the intervention will undergo a second randomisation 1:1 to polarised (n = 150) or non-polarised
(n = 150) dermatoscope. Patient-led surveillance comprises an educational booklet, skin self-examination (SSE)
instructional videos; 3-monthly email/SMS reminders to perform SSE; patient-performed dermoscopy with
teledermatologist feedback; clinical review of positive teledermoscopy through fast-tracked unscheduled clinic visits;
and routinely scheduled clinic visits following each clinician’s usual practice. Clinician-led surveillance comprises an
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educational booklet and routinely scheduled clinic visits following each clinician’s usual practice.
The primary outcome, measured at 12 months, is the proportion of participants diagnosed with a subsequent new
primary or recurrent melanoma at an unscheduled clinic visit. Secondary outcomes include time from
randomisation to diagnosis (of a subsequent new primary or recurrent melanoma and of a new keratinocyte
cancer), clinicopathological characteristics of subsequent new primary or recurrent melanomas (including AJCC
stage), psychological outcomes, and healthcare use. A nested qualitative study will include interviews with patients
and clinicians, and a costing study we will compare costs from a societal perspective. We will compare the
technical performance of two different models of dermatoscope (polarised vs non-polarised).
Discussion: The findings from this study may inform guidance on evidence-based follow-up care, that maximises
early detection of subsequent new primary or recurrent melanoma and patient wellbeing, while minimising costs
to patients, health systems, and society.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12621000176864. Registered on
18 February 2021.
Keywords: Melanoma, Cancer surveillance, Early detection of cancer, Self-examination, Teledermoscopy, Telehealth,
Randomised controlled trial, Health services research
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Introduction
Background and rationale {6a}
Melanoma incidence continues to increase in many
countries worldwide. In Australia, the total number of
people diagnosed with new melanomas increased from
3526 in 1982 to 14,485 in 2016, and the age-standardised
rate increased from 27.9 per 100,000 in 1982 to 54 per
100,000 in 2016 [1]. This appears to be largely driven by
increased early detection of early-stage melanoma before
it has spread from the skin (in situ (stage 0) melanoma,
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and stage I–II invasive melanoma, together > 95% of all
new melanoma diagnoses in Australia) [2]. After surgical
excision of the melanoma, these patients are at risk of de-
veloping a subsequent new primary melanoma, a recur-
rence of their treated primary melanoma, and new
keratinocyte (non-melanoma) skin cancers. Therefore, it is
typically recommended that they undergo at least 10 years
follow-up (and often longer), at intervals ranging from 3
to 12months depending on melanoma stage [3, 4]. Pa-
tients diagnosed with an early-stage melanoma have a very
good prognosis in terms of life expectancy: those with
melanoma in situ (stage 0) have the same mortality risk as
the general population, and those with thin melanomas (<
0.8 mm, which accounts for 65% of all invasive melano-
mas) have a 20-year survival of 80–96% [5–7]. Clinician-
led surveillance in the form of routinely scheduled clinic
visits is widely accepted as the usual model of follow up
care after removal of a melanoma, under the assumption
that this leads to earlier detection and treatment a subse-
quent new primary or recurrent melanoma, and reduced
mortality. However, there is no direct evidence that
clinician-led surveillance leads to improved survival [4, 8].
There is a need to balance the potential benefits of
clinician surveillance for a subsequent new primary or
recurrent melanoma, and keratinocyte skin cancers,
against costs and possible psycho-social harms of fre-
quent routinely scheduled clinic visits and investigations
[9, 10]. The costs of follow-up for early-stage melanoma
are substantial and have been estimated at AU$44M
over 5 years for American Joint Committee of Cancer
(AJCC7) stage I/II [11]. Routinely scheduled clinic visits
also cause opportunity costs in terms of clinician and
patient time and could cause delays in the assessment of
new patients who might benefit from more timely evalu-
ation and treatment. Patients also incur travel and park-
ing expenses, which may be especially burdensome for
those who do not live close to the treatment centre.
Fewer routinely scheduled clinic visits may have little
impact on the detection of subsequent new primary or
recurrent melanomas [12] and could result in substantial
cost savings [13–15].
In addition to these considerations, the ongoing
climate emergency and novel coronavirus (COVID-19)
pandemic are both contributing to a growing and
urgent need to re-consider how healthcare service is
delivered [16, 17]. Other models of follow-up, includ-
ing those using telehealth, present an opportunity to
potentially decrease low value or unnecessary care
[18], reduce environmental impacts of healthcare [17],
and reduce nosocomial infection risk [19]. Telehealth
may be especially valuable in the Australian context
where a up to 30% of the population live remote to
the major cities [20].
Patient-led surveillance is a new model of follow-up
care for patients with a history of early-stage melanoma.
Compared to the traditional clinician-led approach,
there is increased reliance on patient self-management
of their melanoma risk, with increased support for skin
self-examination (SSE), fast-tracked access to unsched-
uled clinic visits should the patient identify a concerning
lesion, and the potential for fewer routinely scheduled
clinic visits [21]. Self or partner-detection of abnormal-
ities may allow early detection of a subsequent new pri-
mary or recurrent melanoma, which may increase the
effectiveness of treatment, and improve survival [22–25].
Although SSE is universally recommended by clinical
guidelines, SSE education and practice remain subopti-
mal [21, 26]. Studies to date suggest that few people
carry out SSE thoroughly and many fail to complete im-
portant components such as checking hard-to-see loca-
tions like the scalp, seeking assistance from someone
else, and documenting changing lesions [27]. Previous
survey and interview studies with people undergoing
melanoma follow-up have shown a need for increased
support for SSE, and acceptance of decreased frequency
of routinely scheduled follow-up if recommended by
their clinician [21, 28]. Additionally, clinicians are more
likely to recommend fewer routinely scheduled clinic
visits if they are confident of the patient’s ability to con-
duct SSE [29].
Digital technologies offer accessible platforms to
facilitate SSE support and consolidate the behaviour
changes needed for patient-led surveillance. Smartphone
and web-based applications (apps) can prompt, remind,
instruct, and record results from SSE, and facilitate tele-
dermoscopy through the transmission of digital images
taken by the patient, to a dermatologist for review. The
Achieving Self-directed Integrated Cancer Aftercare
(ASICA) Skin Checker app has been found to be feasible
and acceptable for supporting SSE and triaging clinical
review [30]. Studies on the preliminary assessment of
diagnostic accuracy of patient-performed mobile teleder-
moscopy have demonstrated feasibility and acceptability
for skin surveillance [31, 32]. Our pilot randomised con-
trolled trial in patients with early-stage melanoma (n =
100) demonstrated the feasibility of a patient-led surveil-
lance intervention that incorporated both the ASICA
app and patient-performed mobile teledermoscopy
(manuscript in preparation) [33]. This intervention also
appeared to improve knowledge, attitudes, and practice
of SSE, and to increase the early detection of subsequent
new primary melanomas, with no adverse psychological
outcomes. A larger sample is needed to confirm or re-
fute these preliminary findings on the effects of patient-
led surveillance.
To address these evidence gaps, we will conduct the
MELanoma SELF surveillance (MEL-SELF) study. This
Ackermann et al. Trials          (2021) 22:324 Page 3 of 18
article presents the protocol for a randomised control
trial that aims to test the hypotheses that patient-led
surveillance results in better health and psychological
outcomes than clinician-led surveillance and consumes
fewer healthcare resources (if implemented as a replace-




To assess whether patient-led surveillance (compris-
ing: smartphone supported SSE, teledermatology, fast-
tracked unscheduled clinic visits in addition to rou-
tinely scheduled clinic visits) compared to clinician-
led surveillance (usual care using treating doctor’s
usual processes for fast-tracked unscheduled and for
routinely scheduled clinic visits) increases the propor-
tion of participants who are diagnosed with a subse-
quent new primary or recurrent melanoma at a fast-
tracked unscheduled clinic visit.
Secondary objectives
To assess the impact of patient-led vs clinician-led sur-
veillance on:
1. Time from randomisation to diagnosis of a
subsequent new primary or recurrent melanoma
and of a keratinocyte cancer.
2. Psychological outcomes using validated scales for
fear of new or recurrent melanoma, general anxiety,
stress, and depression.
3. Skin self-examination:
I. confidence in, knowledge of, attitudes to, and beliefs
about skin self-examination;
II. adherence to recommended skin self-examination
practice.
4. Acceptability of a reduction in routinely scheduled
clinic visit frequency.
5. Resource use through measurement of:
I. number of lesions surgically excised;
II. number of follow-up visits attended (both scheduled
and unscheduled).
And to:
6. Evaluate the technical performance of two different
models of mobile dermatoscope, which patients can
attach to their smartphones.
7. Assess the acceptability of patient-led surveillance
to patients and clinicians (nested qualitative study).
8. Assess resource use and costs for healthcare system,
patient, and environment (costing study).
Trial design {8}
This two-arm, parallel, superiority randomised con-
trolled trial will recruit 600 participants with a 1:1 allo-
cation ratio between intervention and control groups
(see Fig. 1 for trial flow diagram). A second randomisa-
tion step within the intervention arm will randomise
participants 1:1 into alternative models of mobile derma-
toscopes (polarised or non-polarised light source). This
will allow robust evaluation of the technical performance
of models with differing price points that represent the
range of technologies currently on the market [34]. The
primary outcome and secondary outcomes for the inter-
vention group (both models of dermatoscope combined)
will be compared to the control group.
Costing study
This will estimate costs to the health care system and to
patients for the intervention and control groups. All
costs associated with skin self-examination, follow-up
clinics, management of newly identified lesions, and any
other out of pocket costs will be included. We will pro-
vide total costs, and disaggregated costs for different
types of activity within the intervention and control
groups (e.g. separate cost estimates for fast-tracked un-
scheduled clinic visits and for routinely scheduled clinic
visits). We will also measure and value all resources, and
estimate the carbon emissions associated with melanoma
surveillance activities in the intervention and control
groups using established methods for carbon costing
[35, 36]. Further details will be available in the trial’s
costing study protocol and health economic analysis
plan (manuscript in preparation).
Nested qualitative study
A nested qualitative study will explore patients’ and
clinicians’ satisfaction with the intervention and its
acceptability and explore components which may need
to be changed for implementation into routine clinical
practice (see section 20a and Supplementary file 3).





 Have completed treatment for early-stage (defined
as stages: in situ/I/II) melanoma and are attending
regular melanoma follow-up as indicated by at least
one routinely scheduled visit booked within the next
12 months at a recruiting treatment centre;
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Fig. 1 Study flow diagram
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 Are able to conduct SSE;
 Have a suitable study partner (spouse, partner,
family member, friend) to help with SSE;
 Own a smartphone (and have access to internet,
email, and SMS text messaging)
 Routinely scheduled clinic visit frequency at the
treatment centre is 6 monthly or less frequent
 Are able to give informed consent
 Has sufficient English language skills to read the
materials and complete the questionnaires
 Are at least 18 years of age
Exclusion criteria
Patients who:
 Have ever had stage III/IV melanoma.
 Have a known past or current diagnosis of cognitive
impairment.
 Participated in the MEL-SELF pilot trial (conducted
Nov 2018–Feb 2020) [33].
 Own a smartphone that is not compatible with the
mobile dermatoscopes that are part of the
intervention.
Study setting {9}
Individuals who meet the eligibility requirements will be
recruited from three sites in New South Wales (NSW),
Australia. These are at the Royal Prince Alfred Hospital
and the Melanoma Institute Australia (North Sydney),
which are specialist-led clinics in metropolitan Sydney,
and the Newcastle Skin Check clinic, which is a primary
care skin cancer clinic run by general practitioners lo-
cated in metropolitan Newcastle. Further sites may be
opened if needed to meet the recruitment target and
may include regional clinics.
Who will take informed consent? {26a}
Participating clinicians will identify patients attending
their clinic who are eligible for the trial. During this
consultation, clinicians will discuss the research study
with the patient, answer any questions, and identify a
target lesion which the participant will monitor during
the study (the most concerning or remarkable lesion
that the treating doctor would like to monitor for
changes). Following this visit, research study staff will
email the patient with an invitation package comprising
an invitation letter, participant information sheet and a
link to an online consent form (eConsent will be
provided in an online data collection platform, REDCap
[37, 38] hosted by The University of Sydney). Potential
participants will be informed that participation is
voluntary and that their decision about participating will
have no impact on their clinical care. Research study
staff will telephone patients who do not complete their
consent form within 2 weeks. If the patient does not
return their consent form after this telephone call, no
further contact will be made, and this information will
be recorded.
Active run-in phase
Once participants provide eConsent, research study staff
will email participants with instructions to:
 complete an online baseline questionnaire;
 log-in to the web-based ASICA skin checker plat-
form, view instructional videos, and undertake
guided total skin self-examination and electronic
reporting of their findings;
 upload a macroscopic digital photo using their
smartphone of the predetermined target lesion
(chosen by the treating clinician) and a photo of
their back (to document the amount of sun damage
to provide dermatologists with an indicator of
melanoma risk) to REDCap.
Eligible patients who consent to participate and
complete all the run-in activities within 2 months of
consenting, including submission of photos of sufficient
quality to allow dermatological assessment, will be
randomised.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
On the eConsent form, participants will be asked for
permission for their doctors, other health professionals,
hospitals or laboratories, the NSW Cancer Registry, to
release information to The University of Sydney
concerning their disease and treatment for the purposes
of this project. Specific consent for linkage to Medicare
claims data will be sought using the Services Australia
approved template. Participants will be asked to consent
to the storage and use of their skin images during the
research project and for future use. Future use may
involve further comparison of the performance of the
two dermatoscope devices, and comparison of
teledermatology reports across different dermatologists.
This trial does not involve collecting biological
specimens for storage.
Interventions
Explanation for the choice of comparators {6b}
Usual care for early-stage melanoma patients in
Australia comprises routinely scheduled visits as recom-
mended by treating clinicians, with the possibility of
scheduling additional visits if needed, and information
pamphlets on melanoma early detection; therefore, these
conditions will be applied to the control arm. The inter-
vention arm will include all the same conditions as the
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control arm, in addition to teledermatology supported
SSE—this is a potential new approach to patient follow-
up.
Intervention description {11a} Trial participants in the
control arm will receive clinician-led surveillance (usual
care), which involves:
 An educational booklet ‘Your guide to early
melanoma’;
 Routinely scheduled clinic visits as recommended by
their treating clinician (likely to be at intervals
between 6 and 12 months);
 Unscheduled clinic visits, if needed (not prompted
through teledermatology)
Trial participants in the intervention arm will receive
the intervention (patient-led surveillance) as an adjunct
to their usual care, including:
 An educational booklet ‘Your guide to early
melanoma’;
 Routinely scheduled visits as recommended by their
treating clinician;
 Unscheduled clinic visits, if needed (not prompted
through teledermatology);
 Continued access to the ASICA skin checker
instructional videos on how to perform SSE
(including checking for locoregional recurrence) [30,
39];
 A mobile dermatoscope (with a polarised or non-
polarised light source) to attach to their phone, with
detailed written and video instructions on how to
use the smartphone app and dermatoscope
 Training for themselves and a partner/friend/
support person in using the dermatoscope and app,
delivered one-on-one by web conferencing;
 Email or SMS text reminders every 3 months to
perform SSE;
 Teledermatology (see Fig. 2)
Criteria for discontinuing or modifying allocated
interventions {11b}
The assigned study intervention may need to be
modified or discontinued by trial investigators for
various reasons including:
 Harms and safety issues as detailed in sections 22
and 30.
 Participant nonadherence. Less frequent submission
of images could be offered to participants if
necessary.
Study participants will be retained in the trial
whenever possible to enable follow-up and measurement
of primary and secondary outcomes.
Strategies to improve adherence to interventions {11c}
Strategies to improve participant adherence to the
intervention include:
 Participants will receive an overall schedule of trial-
related tasks, and automated reminders delivered via
text messages (SMS) and emails. These will be sup-
plemented by additional SMS, email, and phone calls
from research study staff, if tasks are overdue.
 There will be detailed initial training and
participants will have ongoing access to written and
video instructions on the use of the smartphone app
and dermatoscope.
 Participants will have direct access to research study
staff via text messaging with phone calls and web-
conferencing arranged as needed.
We will report the number and proportion of
participants adhering to three-monthly image submis-
sion (intervention group only) and using non-trial mel-
anoma surveillance including telehealth and other
imaging tests for the skin (intervention and control
groups).
Fig. 2 Teledermatology process
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Relevant concomitant care permitted or prohibited
during the trial {11d}
There are publicly available apps and other forms of
telehealth that assess the risk of melanoma in pigmented
lesions using a smartphone camera and automated
analysis. Recent systematic reviews have found that
these were not of sufficient quality to be recommended,
as the apps have low sensitivity in detecting melanoma
and may give false reassurance to patients [40, 41].
Current clinical practice guidelines recommend against
the use of publicly available melanoma apps. The
participant information sheet advises patients that these
apps are not recommended. We will measure participant
use of non-trial technologies for melanoma detection by
questionnaire at 6 and 12months and will adjust for this
at the analysis stage.
Provisions for post-trial care {30}
All participants will return to usual care after the trial.
As part of our safety protocol, we will monitor the self-
reported questionnaires measuring depression, anxiety,
and stress (DASS-21). Any participants with scores
above the “severe” threshold will be contacted by the site
coordinator who will indicate concern, ask if they would
like help/support, and offer to facilitate this through
contact with the treatment team who would manage re-
ferrals (the thresholds we will use are: depression sub-
scale ≥ 11, anxiety subscale ≥ 8, and stress subscale ≥ 13).
Outcomes {12}
Primary outcome
(M1) Proportion of participants who are diagnosed with
a subsequent new primary or recurrent melanoma (any
stage) at a fast-tracked unscheduled clinic visit during
the 12 months follow-up after randomisation Melano-
mas are histologically confirmed and centrally reviewed
by the trial dermatopathologist (RAS), who will be
blinded to study arm. Classification of a visit as fast-
tracked unscheduled vs routinely scheduled will be done
by the endpoint adjudication committee based on the
participant’s clinic letters, blinded to study arm.
Secondary outcomes
(M2) Time to diagnosis of a new skin cancer: time from
randomisation to the histopathology diagnosis of a
melanoma or keratinocyte skin cancer (as defined by the
date on the histopathology report).
(M3) Pathological characteristics of new skin cancers:
including thickness, stage, and other prognostic factors
(melanomas and keratinocyte skin cancers).
(M4) Skin Self Examination (SSE) including:
M4.1. Thoroughness, confidence, beliefs, attitude, and
knowledge of SSE will be assessed by items adapted
from Janda et al. [42].
M4.2. Adherence with recommended SSE practice
(total body self-examination conducted three-monthly);
Participants will be asked how often they perform a
complete examination of their skin.
(M5) Fear of new or recurrent melanoma (FCR)
severity: assessed using a modified (i.e. melanoma-
specific) version of the 9 item FCR Inventory severity
subscale, the most comprehensive multi-dimensional
scale of FCR available [10]. A higher score indicates
greater FCR.
(M6) General anxiety, stress and depression: measured
using the short version of the Depression Anxiety and
Stress Scales (DASS-21) [43]. The DASS-21 is a set of
three 7-item self-report scales designed to measure the
emotional states of depression, anxiety, and stress.
(M7) Acceptability of hypothetical reduction in
scheduled clinic visit frequency: measured through
questionnaire items designed specifically for this study.
(M8) Number of lesions surgically evaluated:
measured through interrogation of clinic data.
(M9) Number of clinic visits attended: (routinely
scheduled and fast-tracked unscheduled clinic visits)
measured through clinic data.
(M10) Resource use: Costs to the health system and to
patients in each arm of the trial will be estimated using
an online resource use diary. The diary will be used to
document and measure health service use - such as
doctors’ clinic visits, other health practitioner
consultations, imaging and other tests, hospital visits,
and time taken to take and submit images for
teledermatology. The diary will also document days out-
of-role (including paid and unpaid work) and travel
costs. The diary will be based on existing resource use
questionnaires and the patient diary used in the MEL-
SELF pilot study.
(M11) Carbon emissions: carbon costs of resources
used, estimated using established carbon accounting
methods [35, 36].
(M12) Qualitative results: telephone interviews with a
sub-set of intervention group participants at baseline, 6
months and 12 months after randomisation and control
group participants at 12 months to explore, in depth, pa-
tients’ experiences from participation in the trial. We
will also interview clinicians to explore their experience
of the benefits and limitations of the intervention. A
protocol for the nested qualitative study is included in
Supplementary file 3.
(M13) Technical performance of dermatoscopes:
participant ability to submit images (adherence with 3
monthly image submission), participant satisfaction with
dermatoscope, quality of the images (measured using a
checklist developed and tested in another
teledermatology study [44]), any device deficiencies
reported.
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Participant timeline {13}
The components and timing of enrolment activities,
interventions, and assessments for participants are
shown in Fig. 3. Follow up will continue for 12 months.
Participants in the intervention group will perform SSE
and submit images at baseline (post-randomisation), 3,
6, 9, and 12months post randomisation. Outcomes will
be assessed by participant-reported questionnaires at
baseline (pre-randomisation), 6 and 12months after
randomisation.
Sample size {14}
Assuming that 6–8% of patients in the clinician-led sur-
veillance group have a subsequent new primary or recur-
rent melanoma diagnosed within the 12months follow
up [21, 45] and that 1% have a diagnosis through a fast-
tracked unscheduled clinic visit, we will need to recruit
at least 452 participants (226 to patient-led surveillance
and 226 to clinician-led surveillance) in order to have at
least 80% power to detect a 5% absolute increase in the
patient-led surveillance group (i.e. 6% have new or re-
current melanoma diagnosed through unscheduled visit
at treatment centre). Assuming up to 25% of study par-
ticipants withdraw consent or dropout, we will recruit
600 participants (300 to patient-led surveillance and 300
to clinician-led surveillance). These calculations assume
a two-sided 5% significance level and were done using
Fisher’s exact test. This sample size will also ensure at
least 80% power to detect a hazard ratio of 1.71 for time
from randomisation to diagnosis of a skin cancer for the
patient-led vs clinician-led surveillance groups (due to
earlier and increased detection in the patient-led group).
This calculation assumes a 20% event rate in the
clinician-led surveillance group [21, 45] (60 events
among 300 control participants), a 32% event rate in the
patient-led surveillance group (96 events among 300
intervention participants), and 26% event rate overall
(156 events among 600 trial participants).
For the nested qualitative study, we will aim to recruit
30–45 participants, which may vary depending on the
saturation of themes but is a sample size commonly
sufficient to reach saturation in themes and topics [46].
Recruitment {15}
Strategies for achieving adequate participant enrolment
include training and support for clinical staff at each
site, provision of one-page flyers for patients in clinic
waiting rooms, provision of one-page summary of the
trial tasks for recruiting clinicians, and regular monitor-
ing of recruitment targets. Administrative data from the
Melanoma Institute Australia (MIA), indicates that ap-
proximately 800–900 new patients are treated for early
melanoma at MIA each year and approximately 50%
then attend regular follow-up at MIA (includes MIA
clinics in North Sydney and Royal Prince Alfred Hospital
clinics) [47]. The pilot trial found that 21% of people
screened were randomised [33]. Thus, recruiting 600 pa-
tients over 2 years from all patients with a history of
early melanoma who are attending follow-up (new and
existing patients) at MIA, Royal Prince Alfred Hospital
or the GP-run Newcastle Skin Check clinics appears
feasible.
Assignment of interventions: allocation
Sequence generation {16a}
Participants will be randomly assigned to either control
or intervention arms with a 1:1 allocation ratio.
Minimisation will be used to ensure the study groups
are balanced on key prognostic factors:
 Specialist versus GP led clinic (two specialist clinic
sites =Melanoma Institute Australia/Royal Prince
Alfred Hospital and one GP led site Newcastle Skin
Check)
 Patient age (age groups = 18–39, 40–70, 71+)
 Gender (male, female, other)
 Melanoma stage (Stage 0, IA, IB, IIA, IIB, IIC)
 Risk of a subsequent new primary melanoma (1-year
absolute risk score < 5%, 5–10%, > 10% [48]).
 Dysplastic naevus syndrome (yes or no).
Within the intervention arm, participants will be
randomised 1:1 to one of the two models of mobile
dermatoscope (see Fig. 4). The method of
randomisation to type of device will be by permuted
blocks of varying size and stratified by key variables
that might influence adherence with the device
(potential confounders for the secondary outcome
being evaluated for this comparison): site, age, and
gender. The ratio will be adapted depending on
adherence with submission of images that are of
sufficient quality for teledermatology reporting. After
60 participants have been randomised into the
intervention group, we will measure the proportion of
intervention participants who have had an image
reported on at one month after their baseline images
(post randomisation) were due. If there is > 30%
absolute difference in the proportion of intervention
participants who have had an image reported on,
participants who are subsequently enrolled will be
randomised 2:1 to the dermatoscope model where
more participants had an image reported on. If there
is > 50% absolute difference in the proportion of
intervention participants who have had an image
reported on, then all participants who are
subsequently enrolled will be randomised to
dermatoscope model where more participants had an
image that was reported on.
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Concealment mechanism {16b}
Participants will be randomised using the University of
Sydney’s NHMRC Clinical Trials Centre’s Interactive
Voice Response System (IVRS) which is a centralised
telephone randomisation service. Allocation
concealment will be ensured as the service will not
provide the randomisation code until the patient has
been recruited into the trial.
Implementation {16c}
After participants have successfully completed the active
run-in phase, the site coordinator will telephone the
IVRS to perform random allocation and record the
assigned treatment arm. The site coordinator will then
distribute control and intervention packages to the
participants.
Assignment of interventions: blinding
Who will be blinded? {17a}
Blinding of participants, site staff and treating clinicians
will not be possible in this trial. However, the
teledermatologist who assesses the images submitted by
participants in the intervention group will be blinded to
the patient’s identity. For the primary outcome, the trial
dermatopathologist will review the histopathology of all
new melanoma diagnoses made during follow up
blinded to study group allocation, and the endpoint
adjudication committee will review the classification of
Fig. 3 Participant schedule
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clinic visit as routinely scheduled or as fast-tracked un-
scheduled blinded to study group allocation. Where pos-
sible, the endpoint adjudication committee will also
review other secondary outcomes, blinded to study
group allocation.
Procedure for unblinding if needed {17b}
The design is open label with only outcome assessors
being blinded so unblinding will not occur.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Demographic and clinical information At baseline,
demographic and other risk factor information including
age, sex, Indigenous status, non-English language back-
ground, marital status, children, occupation, income,
highest education level, postcode, brand of smartphone
owned, baseline use of digital technology/internet, risk
of a subsequent new primary melanoma and keratino-
cyte cancer [48–50] and personal history of diagnosed
depression or anxiety will be collected using standar-
dised items from the Australian Census questionnaire
and other instruments, where appropriate. Clinical infor-
mation including time since first melanoma diagnosis,
and characteristics of prior melanoma(s) including AJCC
sub-stage and site, will be retrieved from administrative
datasets at the clinics.
Questionnaires During the active run-in phase partici-
pants will complete a baseline questionnaire and follow
up questionnaires will be completed at 6 months and 12
months after randomisation. These questionnaires will
collect data on SSE practice and beliefs [42], level of fear
of new or recurrent melanoma [10], general stress, anx-
iety and depression (DASS-21) [43] and acceptability of
reducing scheduled clinic visit frequency. Participants
will complete questionnaires online through REDCap.
Access codes and reminders will be sent to participants
via email and SMS.
Patient diaries Patient out of pocket and health system
costs associated with each arm of the trial will be
estimated using an online monthly resource use diary
[51, 52]. The diary will be used to document and
measure health service use - such as melanoma clinic
visits, other health practitioner consultations, imaging
and other tests, hospital visits, and time taken to take
and submit images for teledermatology. We will ask
patients to report the number of trips made to their
melanoma follow-up clinic and the mode of transport
used. We will also ask patients to report any visits to
other physicians for a skin lesion excision or other skin
cancer-related procedures. The time each patient spends
to take and submit images, and check teledermatology
reports (intervention group) will be recorded. The diary
will also document informal caregiver (carer) days out-
of-role (including paid and unpaid work), travel costs
and direct carer costs.
Images and teledermatology reports At baseline and 3
monthly intervals to 12 months post randomisation,
Fig. 4 Two-stage randomisation in MEL-SELF trial. *Polarised device refers to cross-polarised light dermatoscope, and non-polarised device refers
to natural light dermatoscope
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intervention participants will be asked to take images
using the mobile dermatoscope attached to their phone.
They will use the corresponding app for the
dermatoscope on their phone to submit the images to
the corresponding web-based platform where the tele-
dermatologist, site coordinator and research study staff
can view them. Teledermatologists will use the same
web platform to make and submit their reports on the
lesions, which are then relayed to participants through
the smartphone app. The teledermatology reports are
also stored on the web platform for access by the re-
search study staff.
Pathology The research study staff will review
participants’ medical records to collect and upload data
including documents confirming eligibility (pathology
reports and/or doctors’ letters) into REDCap. They will
also confirm the number of skin lesions biopsied or
removed and the number of melanomas and
keratinocyte skin cancers diagnosed. The research study
staff will upload source information including letters and
pathology reports associated with excisions. After
completion of the trial, any melanomas diagnosed
during the trial will be reviewed by an expert
dermatopathologist who is blinded to study arm, to
confirm or refute the diagnosis. These reviews will be
stored on REDCap.
Linkage At completion, trial data will be linked with site
databases for a schedule of clinic appointments,
procedures, and pathology, and with the New South
Wales (NSW) Cancer Registry and the Medicare
Benefits Schedule claims database.
Plans to promote participant retention and complete
follow-up {18b}
Participant retention and withdrawals
We will promote participant retention through regular
contact with the research study staff, with SMS text,
email, or phone reminders to complete study activities.
We will tabulate the number of patients whose consent
for trial participation is withdrawn by the participant
and those who are withdrawn by the research study staff
due to loss to follow-up or if they move outside of
NSW. Participants may choose to withdraw from active
follow-up but consent to the ongoing passive collection
of data (clinic, Cancer Registry and Medicare Benefits
Scheme claims database) during the follow-up period.
We will present descriptive summaries for the number
of people who withdraw or are lost to follow-up, with
present separate results for each category (type of with-
drawal and loss to follow-up).
End of study Active participation will continue for 12
months following randomisation or until all trial tasks
have been completed (end dates will be staggered for
individual participants and they will not be able to
submit data after they have finished the 12months
follow up). We will collect linked data from the clinics,
Cancer Registry and Medical Benefits Scheme for a
further 12 months post-trial (i.e. 24 months post-
randomisation).
Data management {19}
Data management procedures are detailed in the data
management plan included as Supplementary file 2.
Confidentiality {27}
Research data will be stored in accordance with the
University of Sydney’s Research Data Management
Policy and Research Code of Conduct and will be stored
on University managed and/or sanctioned storage
infrastructure. Data will be secured via a personal login
and data elements restricted by role at the direction of
the Chief Investigator. After data collection, all
identifiers such as participant names will be removed
and replaced by a code. Electronic data will be re-
identifiable for the duration of the project. Participant
contact information (phone number and email address)
will be stored in a quarantined area on REDCap, only
visible to members of the research team who require it
for study-related contact. This restriction will be built
into REDCap user roles. Personal identifiers will be re-
moved at trial completion, and only non-identifiable
data will be stored subsequently.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
A detailed Statistical Analysis Plan will be published
separately with a full description of the statistical
methods that will be used for analysing the primary and
secondary outcomes, planned additional assessments
including subgroup and sensitivity analyses, and
methods to manage missing data (manuscript in
preparation). All analyses will adhere to the intention-
to-treat principle, unless otherwise stated. As a second-
ary analysis, we will also estimate the effect that would
have been observed had all participants adhered to the
protocol.
Primary outcome We will use generalised linear models
to investigate the difference between patient-led and
clinician-led surveillance on the proportion of partici-
pants with a subsequent new primary or recurrent mel-
anoma diagnosed through an unscheduled visit. We will
present the proportion of participants with the primary
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outcome in each randomised group, and the between-
group difference in proportions, along with the p value
and 95% confidence interval (CI). Unadjusted and ad-
justed analyses will also be presented. For the latter, we
will include baseline measurements of important risk
factors for new or recurrent melanoma as covariates in
the model. These will include age, sex, specialist/GP
clinic, melanoma substage, subsequent new primary
melanoma risk score [48] and dysplastic nevus syn-
drome. We will check the appropriate assumptions for
the model. The adjusted and unadjusted analysis will be
presented as an odds ratio along with the 95% CI and p
value.
Secondary outcomes We will assess the effect of
patient-led and clinician-led surveillance on the second-
ary outcome of time to diagnosis of a skin cancer (mel-
anoma or keratinocyte cancer), using Cox proportional
hazards models. We will present unadjusted and ad-
justed analyses. For the latter, we will include the same
covariates as for the primary outcome (important prog-
nostic variables for outcome event). We will check the
proportional hazards assumption using visual inspection
of plots (including Schoenfeld residuals) and corre-
sponding test statistics. Other assumptions to be
checked include if there is non-informative censoring
and if there is a secular trend. All participants will con-
tinue to be followed up unless they have withdrawn their
consent or moved interstate. In the case that they have
withdrawn their consent or moved interstate, partici-
pants will be censored at the last available follow-up.
The unadjusted and adjusted hazard ratios with 95% CI
and p values will be reported. If the assumptions includ-
ing the proportional hazards assumptions are violated,
these will be addressed as required. The time to diagno-
sis will also be analysed allowing for competing risk of
death.
The appropriate generalised linear model will be used
to assess the remaining secondary outcomes. In general,
Poisson regression will be used for count variables,
logistic regression for proportions and multiple linear
regression for continuous outcome variables. We will
assess effects on continuous outcomes (adherence with
SSE; thoroughness, confidence, beliefs, attitude and
knowledge of SSE; level of fear of new or recurrent
melanoma; general anxiety, stress and depression; and
acceptability of reducing the frequency of routinely
scheduled clinic visits) by including baseline
measurement of the outcome as well as other relevant
prognostic variables as covariates in the multiple linear
regression model. For example, for the outcome: level of
fear of new or recurrent melanoma severity, we will
include baseline measurement of FCRI severity subscale
and personal history of depression or anxiety as
covariates. We will estimate the between-group differ-
ence in change from baseline for each outcome, together
with 95% CI and p values. We will check the appropriate
model assumptions and if any are violated, then we will
use other generalised linear models.
Costing analysis
Using a societal perspective, we will identify, measure
and value all resources used to estimate the costs to
patients, informal caregivers, to the health system, and
to the environment (carbon emissions using relevant
methods) for the intervention and control groups [35].
All costs associated with SSE, skin surveillance and
management of newly identified lesions, out of pocket
costs, opportunity costs and carbon costs will be
included [11]. A detailed data health economics analysis
plan will be developed and published separately.
Nested qualitative study The nested qualitative study
protocol is included in Supplementary File 3 and
analysis is briefly outlined here. We will conduct
telephone interviews at baseline, and at 6 and 12months
follow up among a sub-sample of patients and clinicians
to allow qualitative evaluation of the intervention. We
will invite participants who were randomised to both the
intervention and control arms (controls at 12 months
only) who indicated their interest in taking part in an
interview to explore, in-depth, their experiences in the
trial. A longitudinal format will be applied to interviews
with intervention arm participants (see Supplementary
File 3). Participants who withdraw from the intervention
group will be approached for an interview also. Inter-
views will be audio-recorded and transcribed verbatim.
Interviews with clinicians (n = 5–10) will explore their
experience of the benefits and limitations of the inter-
vention. The study will take a phenomenological per-
spective and will use Framework Analysis [53], a matrix-
based method of thematic analysis which has been used
successfully in other studies of early detection technolo-
gies [54, 55].
Dermatoscope technology comparison sub-study We
will compare performance of the two models of mobile
dermatoscope (cross-polarised light dermatoscope or
natural light dermatoscope) on the following outcomes:
1. Quality of image as reported by teledermatologists.
2. Adherence measured by the proportion of
participants who have an image reported on at each
of the 3 monthly submission points.
3. Participant satisfaction.
4. Protocol deviations, adverse events and device
deficiencies related to use of the dermatoscope, app
or teledermatology platform (for example,
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dermatoscope breakage, incorrect storage or
transmission of images, delayed transmission of
images).
We will measure these outcomes throughout the
active trial period and analyse them using an appropriate
statistical model that allows for repeated measures. The
combination of adherence with the technology and
quality of images will also be used for adaptive
randomisation to protect against poor performance of
one dermatoscope (see section 16).
Interim analyses {21b}
Interim analyses will be conducted by an independent
statistician after 33% of trial participants (approximately
200) have been recruited and, following this, after every
6 months. The interim analyses will be done masked to
randomised groups and will estimate the frequency of
the primary outcome to assess assumptions made for
the sample size calculations, as well as the number of
participants recruited, withdrawals and adverse events.
Separate to the interim analyses described above, there
will be an analysis as part of the adaptive randomisation
after 60 participants have been randomised to the
intervention arm (as described in Section 16). This will
be limited to analysis of the device-related outcomes in
the intervention arm only. There will be no comparison
to the control group or estimation of effect on the pri-
mary outcome or other secondary outcomes for the
adaptive randomisation. Any changes in the ratio of ran-
domisation between the two types of device as a result
of the adaptive randomisation will also be presented to
the Data Safety Monitoring Committee (DSMC).
Methods for additional analyses (e.g. subgroup analyses)
{20b}
Subgroup analyses will be conducted to assess whether
the effect of the intervention on the primary outcome
(patient-led vs clinician-led surveillance) differs across
the following patient characteristics (interaction between
randomisation variable and patient characteristic):
 AJCC melanoma substage
 Risk of a subsequent new primary melanoma (1-year
risk, continuous variable [48])
 Dysplastic naevus syndrome (yes or no)
 Age (continuous variable)
 Confidence in digital technology/digital health
literacy
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
Missing data will be accounted for by sensitivity
analyses. Each variable will be assessed for missing data
and if more than 10% of the data are observed to be
missing on key variables, sensitivity analyses will be
performed using an appropriate analysis method, such as
multiple imputation, instrumental variable analysis or
inverse probability weighting [56]. In addition, a per-
protocol analysis will be conducted on the primary out-
come to estimate the effect that would have been ob-
served had all participants adhered to the protocol.
Plans to give access to the full protocol, participant level-
data and statistical code {31c}
Non-identifiable data and statistical code will be made
available to other approved researchers to maximise the
benefits that can be derived from the data. Access to
NSW Cancer Registry (NSWCR) data requires the
approval of the NSWCR Data Custodian. Access to the
full protocol and to data (other than NSWCR data) may
be requested via the CPI, Associate Professor Katy Bell.
Oversight and monitoring
Composition of the coordinating centre and trial
management committee {5d}
The Trial Management Committee (TMC) will
coordinate the conduct of the trial and is independent of
the trial’s financial sponsorship. TMC members include
KB, MJ, AC, RT, LI, PG, RS, RPMS, VM, MD, JH, RM,
Cl, DL, JT, JE and RAS. TMC responsibilities include
protocol development; study planning, monitoring and
progress; review of information from related research;
and implementation of recommendations from other
study committees and external bodies (e.g. Human
Research Ethics Committee). The Expert Clinician
Reference Group includes medical practitioners who
have specific clinical roles in the trial (e.g.
teledermatologists, treating doctors, pathologists),
contributed to protocol development and provide
ongoing clinical advice. The Trial Coordinating Team
(TCT) consists of project coordinators, data managers
and research assistants and is led by the Coordinating
Principal Investigator (CPI). The TCT is responsible for
the day-to-day management and governance of the trial.
Composition of the data monitoring committee, its role and
reporting structure {21a}
The Data Safety Monitoring Committee (DSMC) will
comprise three trial methodologists (senior statistician(s)
and clinical trialist(s)) who are independent of the study
team. The DSMC will meet to review each interim
analysis and decide on any actions needed, which will be
communicated to the Trial Management Committee.
Adverse event reporting and harms {22}
Please see Supplementary file 4.
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Frequency and plans for auditing trial conduct {23}
Data monitoring and verification Data quality
assurance measures will include:
 Eligibility checks prior to randomisation
 Checks for unusual data patterns or trends
 Rates of recruitment, withdrawals, and losses to
follow-up by site
 Checks for missing or invalid data on the electronic
case report forms (eCRFs).
 Assessment of adverse event reporting rates
compared between sites
 Image data review
Quality assurance processes are available on REDCap,
and the data manager will verify data manually entered
by the research study staff. Trial sites will regularly
provide completed eCRFs to the data manager via
REDCap. Copies of relevant documents for source
verification and quality assurance will be requested,
including imaging scans and histopathology reports.
eCRF submission and query completion rates, as well as
any issues related to protocol compliance, will be
monitored.
On site and remote monitoring Site monitoring will be
scheduled annually for this study (subject to funding and
recruitment rate and at the discretion of the TMC).
Monitoring will address:
 Ongoing training
 Checks for understanding and adherence to trial
protocol, Good Clinical Practice, and regulatory
requirements
 Review of trial procedures (e.g. informed consent
and safety reporting procedures, data capture, eCRF
completion)
 Source data review to check quality and
completeness
 Verification that resources and facilities remain
adequate.
Auditing This study is subject to audit by the TCT
which could occur at any stage of the study. Sites will be
informed in advance in writing, outlining the purpose
and the scope of the audit should one occur.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
The protocol, statistical analysis plan, data safety
management plan, informed consent forms, and
participant education and recruitment materials have
been reviewed and approved by Sydney Local Health
District (RPAH Zone) Ethics committee New South
Wales, Australia. Any subsequent modifications will be
submitted for review, and annual safety and progress
reports will be presented.
Potential protocol modifications will be submitted for
approval by the above human research ethics committee
before being implemented. All relevant parties will be
notified including investigators, participants, and trial
registries.
Dissemination plans {31a}
The research team intends to disseminate outcomes
broadly and at the earliest possible opportunity to allow
access by other researchers and the wider community.
Our findings will be made openly accessible in an
institutional repository or other acceptable location (e.g.
publisher website, subject repositories) within a 12-
month period from the date of publication. Also, rele-
vant stakeholders will be informed including partici-
pants, consumer groups, clinicians, the public and
policymakers. The lay summary of findings will also be
disseminated to consumer networks of Melanoma Insti-
tute Australia, the Australian Melanoma Consumer Alli-
ance, associated charities, and Cancer Voices Australia.
A summary of findings will be prepared for publication
via social media platforms including Facebook and Twit-
ter, newsletters, and press releases and through the Uni-
versity of Sydney’s School of Public Health website.
Discussion
This randomised controlled trial will compare patient-
led surveillance -with clinician-led surveillance for pa-
tients with a history of early-stage melanoma. It will gen-
erate evidence on whether patient-led surveillance can
safely and effectively enable earlier detection of subse-
quent new primary or recurrent melanoma and kera-
tinocyte cancers. It will also provide evidence of the
acceptability of patient-led surveillance to patients and
clinicians and report on the impact on health system re-
sources and patient costs. The study is timely given the
growing interest in digital healthcare services during the
COVID-19 pandemic.
The investigators have considered the potential risks
and impacts of COVID-19 on the conduct of this study.
We plan to protect the health of participants and study
personnel, while also minimising the impact of our study
on the provision of health care, by implementing actions
that reduce the requirement for face to face visits either
temporarily or permanently. These actions will also pro-
tect the scientific integrity of the study.
Clinicians will limit patient face-to-face visits by using
routinely scheduled visits to identify potential partici-
pants, provide an explanation of the research project to
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allow informed consent, and select a target lesion. These
processes may also be achieved in a telehealth consult-
ation where appropriate. We will minimise participant
interactions with researchers. Recruitment packages will
be emailed, and consent, questionnaires and diaries will
be collected online through REDCap. Images will be
uploaded into web-based platforms. Researchers will
provide information and support by telephone and offer
training on the intervention by video web conferencing.
We will supply participants with dermatoscopes via cou-
riers. Study staff will work remotely and meet via video
web conferencing when public health advice recommend
this. An issue related to the scientific integrity of the
trial is that there may be more background telehealth
use and alternative app use than previously. We plan to
collect this information from participants in the baseline
and follow-up questionnaires.
In conclusion, this study will contribute novel findings
on evidence-based follow-up after treatment of early
melanoma, to maximise patient wellbeing and the early
detection of new or recurrent melanoma, while minimis-
ing costs to the patient and health system.
Trial status
The protocol reported here is version 1.0 dated 19
February 2021. Trial recruitment will commence on
approximately 1 July 2021 and will continue until the
recruitment target is achieved and planned follow-up is
completed (approximately 31 June 2023).
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